Evidence map›Paper›PMID 33472665›Full record

ArticleJournal of translational medicine2021

Reduction of miR-744 delivered by NSCLC cell-derived extracellular vesicles upregulates SUV39H1 to promote NSCLC progression via activation of the Smad9/BMP9 axis.

Liming Gao, Qi Tian, Tong Wu, Shanshan Shi, Xiaobo Yin, Lijie Liu, Lei Zheng, Ping Wang, Yaling Tian, Shufeng Xu

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Liming Gao *Department of Oncology, The First Hospital of Qinhuangdao, Qinhuangdao, 066000, P.R. China.
Qi Tian *Department of Respiratory, The First Hospital of Qinhuangdao, No. 258, Wenhua Road, Haigang District, Qinhuangdao, 066000, Hebei, P.R. China.
Tong WuHebei Medical University, Shijiazhuang, 050000, P.R. China.
Shanshan ShiDepartment of Respiratory, The First Hospital of Qinhuangdao, No. 258, Wenhua Road, Haigang District, Qinhuangdao, 066000, Hebei, P.R. China.
Xiaobo YinDepartment of Respiratory, The First Hospital of Qinhuangdao, No. 258, Wenhua Road, Haigang District, Qinhuangdao, 066000, Hebei, P.R. China.
Lijie LiuChengde Medical College, Chengde, 067000, P.R. China.
Lei ZhengDepartment of Oncology, The First Hospital of Qinhuangdao, Qinhuangdao, 066000, P.R. China.
Ping WangDepartment of Respiratory, Chinese PLA General Hospital, Beijing, 100853, P.R. China.
Yaling TianDepartment of Oncology, The First Hospital of Qinhuangdao, Qinhuangdao, 066000, P.R. China.
Shufeng XuDepartment of Respiratory, The First Hospital of Qinhuangdao, No. 258, Wenhua Road, Haigang District, Qinhuangdao, 066000, Hebei, P.R. China. doctorxsf@163.com.
First Hospital of Qinhuangdao · CNChinese PLA General Hospital · CNHebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-small cell lung cancer (NSCLC) is a common type of lung cancer. Extracellular vehicles (EVs) are nano-sized particles containing proteins, lipids, and miRNAs secreted by various cells, which play important roles in the development of lung cancer by regulating a wide range of signaling pathways. This study focused on elucidating a potential mechanism by which EVs promote the development of NSCLC.

methodsExpression levels of miR-744, SUV39H1, Smad9, and BMP4 in clinical tissue samples of NSCLC patients and cell lines were quantified by RT-qPCR and/or western blot analysis. The interaction between SUV39H1 and miR-744 was identified by dual-luciferase reporter assay. miR-744, SUV39H1, and BMP4 expression levels were modulated in A549 and H460 cells, in order to evaluate their effects on cell proliferation, colony formation and cell cycle. A NSCLC xenograft mouse model was used to verify the in vitro findings. NSCLC cell-derived EVs and normal bronchial epithelial cell-derived EVs were isolated and their roles in NSCLC development were evaluated in vivo and in vitro.

resultsmiR-744 expression was lower in cancer cell-derived derived EVs than in normal lung epithelial cell-derived EVs. Reduced miR-744 expression in EVs upregulated SUV39H1 in NSCLC cells and further increased BMP4 levels to promote NSCLC development. BMP4 was upregulated in NSCLC cells upon suppression of Smad9 mediated by SUV39H1. Reduced miR-744 expression transferred from cancer cell-derived EVs into NSCLC cells enhanced cancer development.

conclusionOverall, our findings unveiled a mechanism whereby miR-744 delivered by NSCLC-derived EVs upregulated SUV39H1, activating the Smad9/BMP9 axis and thus promoted cancer development.

Indexed as

Carcinoma, Non-Small-Cell LungExtracellular VesiclesLung NeoplasmsMicroRNAsAnimalsHumansLungMethyltransferasesMiceRepressor ProteinsSmad8 ProteinMethyltransferasesMicroRNAsMIRN744 microRNA, humanMIRN744 microRNA, mouseRepressor ProteinsSmad8 ProteinSMAD9 protein, humanSUV39H1 protein, humanSuv39h1 protein, mouseBMP4miR-744NSCLCSmad9SUV39H1

Identifiers

PMID33472665
PMCPMC7816389
OpenAlexW3123219733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.